Tjebo F C Heeren Selected Research

Telangiectasis (Telangiectasia)

1/2022	Description of a patient cohort with Hereditary Sensory Neuropathy type 1 without retinal disease Macular Telangiectasia type 2 - implications for retinal screening in HSN1.
1/2020	Longitudinal Assessment of Remnant Foveal Cone Structure in a Case Series of Early Macular Telangiectasia Type 2.
10/2019	Serine and Lipid Metabolism in Macular Disease and Peripheral Neuropathy.
1/2019	Contrast sensitivity and visual acuity under low light conditions in macular telangiectasia type 2.
1/2019	Quantification of Retinal and Choriocapillaris Perfusion in Different Stages of Macular Telangiectasia Type 2.
1/2019	Binocular Inhibition of Reading in Macular Telangiectasia Type 2.
1/2019	Estimating Retinal Sensitivity Using Optical Coherence Tomography With Deep-Learning Algorithms in Macular Telangiectasia Type 2.
10/2018	Macular Pigment Distribution as Prognostic Marker for Disease Progression in Macular Telangiectasia Type 2.
1/2018	MACULAR TELANGIECTASIA TYPE 2: Quantitative Analysis of a Novel Phenotype and Implications for the Pathobiology of the Disease.
3/2016	VERY EARLY DISEASE MANIFESTATIONS OF MACULAR TELANGIECTASIA TYPE 2.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tjebo F C Heeren Research Topics

Disease

13	Telangiectasis (Telangiectasia) 01/2022 - 05/2013
4	Atrophy 11/2020 - 05/2013
3	Disease Progression 04/2020 - 10/2018
2	Macular Degeneration (Age-Related Maculopathy) 01/2021 - 01/2021
1	Hereditary Sensory and Autonomic Neuropathies (HSAN) 01/2022
1	Retinal Diseases 01/2022
1	Fibrosis (Cirrhosis) 11/2020
1	Diabetic Retinopathy (Retinopathy, Diabetic) 04/2020
1	Diplopia (Double Vision) 01/2020
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2020
1	Peripheral Nervous System Diseases (PNS Diseases) 10/2019
1	Scotoma (Scintillating Scotoma) 01/2019
1	Geographic Atrophy 01/2016

Drug/Important Bio-Agent (IBA)

15	Retinaldehyde (Retinal)IBA 01/2022 - 05/2013
4	Macular PigmentIBA 01/2019 - 05/2013
2	Serine (L-Serine)FDA Link 01/2022 - 10/2019
2	Retinal Pigments (Pigments, Visual)IBA 01/2016 - 05/2013
1	TransferasesIBA 01/2022
1	Glycine (Aminoacetic Acid)FDA LinkGeneric 01/2022
1	N-acetyltryptophanamide (NATA)IBA 01/2021
1	Bevacizumab (Avastin)FDA Link 01/2021
1	afliberceptIBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 04/2020
1	LipidsIBA 01/2020
1	Serine C-PalmitoyltransferaseIBA 10/2019
1	Amino Acids FDA Link 10/2019
1	Fluorescein (Funduscein)FDA LinkGeneric 01/2016
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2015
1	Ranibizumab (Lucentis)FDA Link 12/2015
1	LuteinIBA 05/2013
1	ZeaxanthinsIBA 05/2013

Therapy/Procedure

2	Therapeutics 01/2021 - 12/2015
2	Telescopes 01/2020 - 01/2019
1	Injections 12/2015